Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 8/2016

16.05.2016 | Original Article

Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study

verfasst von: Mary A. Waterhouse, Elizabeth A. Burmeister, Dianne L. O’Connell, Emma L. Ballard, Susan J. Jordan, Neil D. Merrett, David Goldstein, David Wyld, Monika Janda, Vanessa L. Beesley, Madeleine E. Payne, Helen M. Gooden, Rachel E. Neale

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Patient and health system determinants of outcomes following pancreatic cancer resection, particularly the relative importance of hospital and surgeon volume, are unclear. Our objective was to identify patient, tumour and health service factors related to mortality and survival amongst a cohort of patients who underwent completed resection for pancreatic cancer.

Methods

Eligible patients were diagnosed with pancreatic adenocarcinoma between July 2009 and June 2011 and had a completed resection performed in Queensland or New South Wales, Australia, with either tumour-free (R0) or microscopically involved margins (R1) (n = 270). Associations were examined using logistic regression (for binary outcomes) and Cox proportional hazards or stratified Cox models (for time-to-event outcomes).

Results

Patients treated by surgeons who performed <4 resections/year were more likely to die from a surgical complication (versus ≥4 resections/year, P = 0.04), had higher 1-year mortality (P = 0.03), and worse overall survival up to 1.5 years after surgery (adjusted hazard ratio 1.58, 95 % confidence interval 1.07–2.34). Amongst patients who had ≥1 complication within 30 days of surgery, those aged ≥70 years had higher 1-year mortality compared to patients aged <60 years. Adjuvant chemotherapy treatment improved recurrence-free survival (P = 0.01). There were no significant associations between hospital volume and mortality or survival.

Conclusions

Systems should be implemented to ensure that surgeons are completing a sufficient number of resections to optimize patient outcomes. These findings may be particularly relevant for countries with a relatively small and geographically dispersed population.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hartwig W, Werner J, Jager D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14(11):e476-85.CrossRefPubMed Hartwig W, Werner J, Jager D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14(11):e476-85.CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2):71-96.CrossRefPubMed Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2):71-96.CrossRefPubMed
3.
Zurück zum Zitat Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. JAMA Surg 2015; 150(8):701-710.CrossRefPubMed Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. JAMA Surg 2015; 150(8):701-710.CrossRefPubMed
4.
Zurück zum Zitat Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10(10):1338-1345; discussion 1345-6.CrossRefPubMed Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006; 10(10):1338-1345; discussion 1345-6.CrossRefPubMed
5.
Zurück zum Zitat Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74-85.CrossRefPubMedPubMedCentral Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74-85.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27(17):2855-2862.CrossRefPubMed Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27(17):2855-2862.CrossRefPubMed
7.
Zurück zum Zitat Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg 2013; 257(4):731-736.CrossRefPubMed Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg 2013; 257(4):731-736.CrossRefPubMed
8.
Zurück zum Zitat Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 2009; 11(4):282-289.CrossRef Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 2009; 11(4):282-289.CrossRef
9.
Zurück zum Zitat Haigh PI, Bilimoria KY, DiFronzo LA. Early postoperative outcomes after pancreaticoduodenectomy in the elderly. Arch Surg 2011; 146(6):715-723.CrossRefPubMed Haigh PI, Bilimoria KY, DiFronzo LA. Early postoperative outcomes after pancreaticoduodenectomy in the elderly. Arch Surg 2011; 146(6):715-723.CrossRefPubMed
10.
Zurück zum Zitat Oliveira-Cunha M, Malde DJ, Aldouri A, et al. Results of pancreatic surgery in the elderly: is age a barrier? HPB (Oxford) 2013; 15(1):24-30.CrossRef Oliveira-Cunha M, Malde DJ, Aldouri A, et al. Results of pancreatic surgery in the elderly: is age a barrier? HPB (Oxford) 2013; 15(1):24-30.CrossRef
11.
Zurück zum Zitat Gooiker GA, van Gijn W, Wouters MW, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011; 98(4):485-494.CrossRefPubMed Gooiker GA, van Gijn W, Wouters MW, et al. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg 2011; 98(4):485-494.CrossRefPubMed
12.
Zurück zum Zitat Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137(6):511-520.CrossRefPubMed Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137(6):511-520.CrossRefPubMed
13.
Zurück zum Zitat Killeen SD, O’Sullivan MJ, Coffey JC, et al. Provider volume and outcomes for oncological procedures. Br J Surg 2005; 92(4):389-402.CrossRefPubMed Killeen SD, O’Sullivan MJ, Coffey JC, et al. Provider volume and outcomes for oncological procedures. Br J Surg 2005; 92(4):389-402.CrossRefPubMed
14.
Zurück zum Zitat van Heek NT, Kuhlmann KF, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 2005; 242(6):781-8, discussion 788-790.CrossRefPubMedPubMedCentral van Heek NT, Kuhlmann KF, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 2005; 242(6):781-8, discussion 788-790.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Eppsteiner RW, Csikesz NG, McPhee JT, et al. Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg 2009; 249(4):635-640.CrossRefPubMed Eppsteiner RW, Csikesz NG, McPhee JT, et al. Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg 2009; 249(4):635-640.CrossRefPubMed
16.
Zurück zum Zitat Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349(22):2117-2127.CrossRefPubMed Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349(22):2117-2127.CrossRefPubMed
17.
Zurück zum Zitat Nathan H, Cameron JL, Choti MA, et al. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009; 208(4):528-538.CrossRefPubMed Nathan H, Cameron JL, Choti MA, et al. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009; 208(4):528-538.CrossRefPubMed
18.
Zurück zum Zitat La Torre M, Nigri G, Ferrari L, et al. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2012; 78(2):225-229.PubMed La Torre M, Nigri G, Ferrari L, et al. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2012; 78(2):225-229.PubMed
19.
Zurück zum Zitat Allareddy V, Ward MM, Allareddy V, Konety BR. Effect of meeting Leapfrog volume thresholds on complication rates following complex surgical procedures. Ann Surg 2010; 251(2):377-383.CrossRefPubMed Allareddy V, Ward MM, Allareddy V, Konety BR. Effect of meeting Leapfrog volume thresholds on complication rates following complex surgical procedures. Ann Surg 2010; 251(2):377-383.CrossRefPubMed
20.
Zurück zum Zitat Dimick JB, Pronovost PJ, Cowan JA, Jr., et al. Variation in postoperative complication rates after high-risk surgery in the United States. Surgery 2003; 134(4):534-540; discussion 540-541.CrossRefPubMed Dimick JB, Pronovost PJ, Cowan JA, Jr., et al. Variation in postoperative complication rates after high-risk surgery in the United States. Surgery 2003; 134(4):534-540; discussion 540-541.CrossRefPubMed
21.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6):1227-1234.CrossRefPubMed Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 2007; 110(6):1227-1234.CrossRefPubMed
22.
Zurück zum Zitat Burmeister EA, O’Connell DL, Beesley VL, et al. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Pancreas 2015; 44(8):1259-1265CrossRefPubMed Burmeister EA, O’Connell DL, Beesley VL, et al. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Pancreas 2015; 44(8):1259-1265CrossRefPubMed
23.
Zurück zum Zitat Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 2015; 102(12):1459-1472.CrossRefPubMed Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 2015; 102(12):1459-1472.CrossRefPubMed
24.
Zurück zum Zitat Sobin L, Gospodarowicz M, Wittekind C. The TNM Classification of Malignant Tumours. Seventh ed: Wiley-Blackwell, 2009. Sobin L, Gospodarowicz M, Wittekind C. The TNM Classification of Malignant Tumours. Seventh ed: Wiley-Blackwell, 2009.
25.
Zurück zum Zitat Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology 2011; 22(5):745.CrossRefPubMed Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology 2011; 22(5):745.CrossRefPubMed
26.
Zurück zum Zitat Therneau TM. survival: A Package for Survival Analysis in S. 2015. Therneau TM. survival: A Package for Survival Analysis in S. 2015.
27.
Zurück zum Zitat Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012; 118(10):2674-2681.CrossRefPubMed Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2012; 118(10):2674-2681.CrossRefPubMed
28.
Zurück zum Zitat Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223(5):506-511; discussion 511-512.CrossRefPubMedPubMedCentral Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 1996; 223(5):506-511; discussion 511-512.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 2008; 10(5):371-376.CrossRef Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 2008; 10(5):371-376.CrossRef
30.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6):567-579.CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6):567-579.CrossRefPubMed
31.
Zurück zum Zitat Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 2010; 39(4):458-462.CrossRefPubMed Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 2010; 39(4):458-462.CrossRefPubMed
32.
Zurück zum Zitat de Franco V, Frampas E, Wong M, et al. Safety and feasibility of pancreaticoduodenectomy in the elderly: a matched study. Pancreas 2011; 40(6):920-924.CrossRefPubMed de Franco V, Frampas E, Wong M, et al. Safety and feasibility of pancreaticoduodenectomy in the elderly: a matched study. Pancreas 2011; 40(6):920-924.CrossRefPubMed
33.
Zurück zum Zitat Frakes JM, Strom T, Springett GM, et al. Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol 2015; 6(2):127-132.CrossRefPubMed Frakes JM, Strom T, Springett GM, et al. Resected pancreatic cancer outcomes in the elderly. J Geriatr Oncol 2015; 6(2):127-132.CrossRefPubMed
34.
Zurück zum Zitat Cheung MC, Yang R, Byrne MM, et al. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010; 116(3):723-733.CrossRefPubMed Cheung MC, Yang R, Byrne MM, et al. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010; 116(3):723-733.CrossRefPubMed
35.
Zurück zum Zitat Zell JA, Rhee JM, Ziogas A, et al. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 2007; 16(3):546-552.CrossRefPubMed Zell JA, Rhee JM, Ziogas A, et al. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 2007; 16(3):546-552.CrossRefPubMed
36.
Zurück zum Zitat Pecorelli N, Balzano G, Capretti G, et al. Effect of surgeon volume on outcome following pancreaticoduodenectomy in a high-volume hospital. J Gastrointest Surg 2012; 16(3):518-523.CrossRefPubMed Pecorelli N, Balzano G, Capretti G, et al. Effect of surgeon volume on outcome following pancreaticoduodenectomy in a high-volume hospital. J Gastrointest Surg 2012; 16(3):518-523.CrossRefPubMed
37.
Zurück zum Zitat Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg 2010; 145(7):634-640.CrossRefPubMed Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg 2010; 145(7):634-640.CrossRefPubMed
38.
Zurück zum Zitat Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222(5):638-645.CrossRefPubMedPubMedCentral Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222(5):638-645.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat The Leapfrog Group for Patient Safety. Factsheet: Evidence-based Hospital Referral. 2004. The Leapfrog Group for Patient Safety. Factsheet: Evidence-based Hospital Referral. 2004.
40.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama 2013; 310(14):1473-1481.CrossRefPubMed Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama 2013; 310(14):1473-1481.CrossRefPubMed
41.
Zurück zum Zitat Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101(6):908-915.CrossRefPubMedPubMedCentral Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101(6):908-915.CrossRefPubMedPubMedCentral
Metadaten
Titel
Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study
verfasst von
Mary A. Waterhouse
Elizabeth A. Burmeister
Dianne L. O’Connell
Emma L. Ballard
Susan J. Jordan
Neil D. Merrett
David Goldstein
David Wyld
Monika Janda
Vanessa L. Beesley
Madeleine E. Payne
Helen M. Gooden
Rachel E. Neale
Publikationsdatum
16.05.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 8/2016
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-016-3157-4

Weitere Artikel der Ausgabe 8/2016

Journal of Gastrointestinal Surgery 8/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.